Immix Biopharma, Inc. Annual Income Tax Expense (Benefit) in USD from 2020 to 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Immix Biopharma, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2020 to 2024.
  • Immix Biopharma, Inc. Income Tax Expense (Benefit) for the quarter ending December 31, 2024 was $10.8K, a 33.3% increase year-over-year.
  • Immix Biopharma, Inc. Income Tax Expense (Benefit) for the twelve months ending December 31, 2024 was $41K, a 55.4% increase year-over-year.
  • Immix Biopharma, Inc. annual Income Tax Expense (Benefit) for 2024 was $41K, a 55.4% increase from 2023.
  • Immix Biopharma, Inc. annual Income Tax Expense (Benefit) for 2023 was $26.4K, a 157% increase from 2022.
  • Immix Biopharma, Inc. annual Income Tax Expense (Benefit) for 2022 was $10.3K, a 70.8% increase from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $41K +$14.6K +55.4% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-25
2023 $26.4K +$16.1K +157% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-25
2022 $10.3K +$4.26K +70.8% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-29
2021 $6.01K -$11.5K -65.7% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-27
2020 $17.5K Jan 1, 2020 Dec 31, 2020 10-K 2022-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.